Review





Similar Products

b 59 3 b 2 3 b 0 287  (Becton Dickinson)
86
Becton Dickinson b 59 3 b 2 3 b 0 287
B 59 3 B 2 3 B 0 287, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/b 59 3 b 2 3 b 0 287/product/Becton Dickinson
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
b 59 3 b 2 3 b 0 287 - by Bioz Stars, 2024-12
86/100 stars
  Buy from Supplier
design 59 2014 287 295  (Verlag GmbH)
86
Verlag GmbH design 59 2014 287 295
Design 59 2014 287 295, supplied by Verlag GmbH, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/design 59 2014 287 295/product/Verlag GmbH
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
design 59 2014 287 295 - by Bioz Stars, 2024-12
86/100 stars
  Buy from Supplier
cc pgc1 swe wtccc2 495 547 360 575 112 885 543 93 59 123 287 589 84 137 658 506 226 877  (Tokai)
86
Tokai cc pgc1 swe wtccc2 495 547 360 575 112 885 543 93 59 123 287 589 84 137 658 506 226 877
Cc Pgc1 Swe Wtccc2 495 547 360 575 112 885 543 93 59 123 287 589 84 137 658 506 226 877, supplied by Tokai, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cc pgc1 swe wtccc2 495 547 360 575 112 885 543 93 59 123 287 589 84 137 658 506 226 877/product/Tokai
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
cc pgc1 swe wtccc2 495 547 360 575 112 885 543 93 59 123 287 589 84 137 658 506 226 877 - by Bioz Stars, 2024-12
86/100 stars
  Buy from Supplier
prevention 41 5 238 31 7 287 14 59  (Othera Pharmaceuticals Inc)
86
Othera Pharmaceuticals Inc prevention 41 5 238 31 7 287 14 59
Prevention 41 5 238 31 7 287 14 59, supplied by Othera Pharmaceuticals Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prevention 41 5 238 31 7 287 14 59/product/Othera Pharmaceuticals Inc
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
prevention 41 5 238 31 7 287 14 59 - by Bioz Stars, 2024-12
86/100 stars
  Buy from Supplier
p value total n 662 114 548 sex 0 59 male hpfs 287  (SAS institute)
86
SAS institute p value total n 662 114 548 sex 0 59 male hpfs 287
Clinical and molecular features of colon cancer according to COX-2 expression.
P Value Total N 662 114 548 Sex 0 59 Male Hpfs 287, supplied by SAS institute, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p value total n 662 114 548 sex 0 59 male hpfs 287/product/SAS institute
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
p value total n 662 114 548 sex 0 59 male hpfs 287 - by Bioz Stars, 2024-12
86/100 stars
  Buy from Supplier
59 female 287 none control  (Blackwell Science Ltd)
86
Blackwell Science Ltd 59 female 287 none control
Clinical and molecular features of colon cancer according to COX-2 expression.
59 Female 287 None Control, supplied by Blackwell Science Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/59 female 287 none control/product/Blackwell Science Ltd
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
59 female 287 none control - by Bioz Stars, 2024-12
86/100 stars
  Buy from Supplier

Image Search Results


Clinical and molecular features of colon cancer according to COX-2 expression.

Journal:

Article Title: Cyclooxygenase-2 Expression is an Independent Predictor of Poor Prognosis in Colon Cancer

doi: 10.1158/1078-0432.CCR-08-1841

Figure Lengend Snippet: Clinical and molecular features of colon cancer according to COX-2 expression.

Article Snippet: All analyses used SAS version 9.1 (SAS Institute, Cary, NC) and all p values were two-sided. table ft1 table-wrap mode="anchored" t5 caption a7 Clinical or molecular feature All cases COX-2 negative COX-2 positive P value Total N 662 114 548 Sex 0.59 Male (HPFS) 287 (43%) 52 (46%) 235 (43%) Female (NHS) 375 (57%) 62 (54%) 313 (57%) Mean age ± SD 66.5 ± 8.3 66.8 ± 7.4 66.5 ± 8.4 0.69 Year of diagnosis 0.05 Prior to 1990 101 (15%) 17 (15%) 84 (15%) 1990 to 1999 482 (73%) 91 (80%) 391 (71%) 2000 to 2002 79 (12%) 6 (5.3%) 73 (13%) Tumor location ^ 0.005 Proximal 434 (59%) 80 (71%) 305 (56%) Distal 297 (41%) 33 (29%) 236 (44%) Tumor stage 0.77 I 136 (21%) 25 (22%) 111 (20%) IIA 207 (31%) 40 (35%) 167 (30%) IIB 20 (3.0%) 1 (0.9%) 19 (3.5%) IIIA 21 (3.2%) 2 (1.8%) 19 (3.5%) IIIB 88 (13%) 13 (11%) 75 (14%) IIIC 55 (8.3%) 13 (11%) 42 (7.7%) IV 86 (13%) 15 (13%) 71 (13%) Unknown 49 (7.4%) 5 (4.4%) 44 (8.0%) Tumor grade 0.0003 Low 585 (89%) 90 (79%) 495 (91%) High 74 (11%) 24 (21%) 50 (9.2%) p53 * <0.0001 (-) 404 (61%) 91 (81%) 313 (58%) (+) 253 (39%) 22 (19%) 231 (42%) MSI 0.0009 MSI-low/MSS 521 (81%) 77 (69%) 446 (84%) MSI-high 121 (19%) 33 (31%) 88 (16%) CIMP 0.004 CIMP-0 277 (42%) 32 (28%) 245 (45%) CIMP-low 257 (39%) 53 (46%) 204 (37%) CIMP-high 128 (19%) 29 (25%) 99 (18%) KRAS mutation 0.55 (-) 411 (64%) 68 (61%) 343 (64%) (+) 234 (36%) 43 (39%) 191 (36%) BRAF mutation 0.24 (-) 525 (83%) 85 (79%) 440 (84%) (+) 105 (17%) 22 (21%) 83 (16%) Open in a separate window (%) indicates the proportion of tumors with a specific clinical or molecular feature in a given COX-2 subtype.

Techniques: Expressing, Mutagenesis

COX-2 expression and survival among colon cancer patients

Journal:

Article Title: Cyclooxygenase-2 Expression is an Independent Predictor of Poor Prognosis in Colon Cancer

doi: 10.1158/1078-0432.CCR-08-1841

Figure Lengend Snippet: COX-2 expression and survival among colon cancer patients

Article Snippet: All analyses used SAS version 9.1 (SAS Institute, Cary, NC) and all p values were two-sided. table ft1 table-wrap mode="anchored" t5 caption a7 Clinical or molecular feature All cases COX-2 negative COX-2 positive P value Total N 662 114 548 Sex 0.59 Male (HPFS) 287 (43%) 52 (46%) 235 (43%) Female (NHS) 375 (57%) 62 (54%) 313 (57%) Mean age ± SD 66.5 ± 8.3 66.8 ± 7.4 66.5 ± 8.4 0.69 Year of diagnosis 0.05 Prior to 1990 101 (15%) 17 (15%) 84 (15%) 1990 to 1999 482 (73%) 91 (80%) 391 (71%) 2000 to 2002 79 (12%) 6 (5.3%) 73 (13%) Tumor location ^ 0.005 Proximal 434 (59%) 80 (71%) 305 (56%) Distal 297 (41%) 33 (29%) 236 (44%) Tumor stage 0.77 I 136 (21%) 25 (22%) 111 (20%) IIA 207 (31%) 40 (35%) 167 (30%) IIB 20 (3.0%) 1 (0.9%) 19 (3.5%) IIIA 21 (3.2%) 2 (1.8%) 19 (3.5%) IIIB 88 (13%) 13 (11%) 75 (14%) IIIC 55 (8.3%) 13 (11%) 42 (7.7%) IV 86 (13%) 15 (13%) 71 (13%) Unknown 49 (7.4%) 5 (4.4%) 44 (8.0%) Tumor grade 0.0003 Low 585 (89%) 90 (79%) 495 (91%) High 74 (11%) 24 (21%) 50 (9.2%) p53 * <0.0001 (-) 404 (61%) 91 (81%) 313 (58%) (+) 253 (39%) 22 (19%) 231 (42%) MSI 0.0009 MSI-low/MSS 521 (81%) 77 (69%) 446 (84%) MSI-high 121 (19%) 33 (31%) 88 (16%) CIMP 0.004 CIMP-0 277 (42%) 32 (28%) 245 (45%) CIMP-low 257 (39%) 53 (46%) 204 (37%) CIMP-high 128 (19%) 29 (25%) 99 (18%) KRAS mutation 0.55 (-) 411 (64%) 68 (61%) 343 (64%) (+) 234 (36%) 43 (39%) 191 (36%) BRAF mutation 0.24 (-) 525 (83%) 85 (79%) 440 (84%) (+) 105 (17%) 22 (21%) 83 (16%) Open in a separate window (%) indicates the proportion of tumors with a specific clinical or molecular feature in a given COX-2 subtype.

Techniques: Expressing